O S Mabrouk1, I J Dripps2, S Ramani2, C Chang2, J L Han3, K C Rice4, E M Jutkiewicz5. 1. Neurolytical LLC, Ann Arbor, MI, United States; Department of Pharmacology, Ann Arbor, MI, United States; Department of Chemistry, University of Michigan, Ann Arbor, MI, United States. 2. Department of Pharmacology, Ann Arbor, MI, United States. 3. Department of Chemistry, University of Michigan, Ann Arbor, MI, United States. 4. Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States. 5. Department of Pharmacology, Ann Arbor, MI, United States. Electronic address: ejutkiew@umich.edu.
Abstract
BACKGROUND: Monitoring mouse behavior is a critical step in the development of modern pharmacotherapies. NEW METHOD: Here we describe the application of a novel method that utilizes a touch display computer (tablet) and software to detect, record, and report fine motor behaviors. A consumer-grade tablet device is placed in the bottom of a specially made acrylic cage allowing the animal to walk on the device (MouseTrapp). We describe its application in open field (for general locomotor studies) which measures step lengths and velocity. The device can perform light-dark (anxiety) tests by illuminating half of the screen and keeping the other half darkened. A divider is built into the lid of the device allowing the animal free access to either side. RESULTS: Treating mice with amphetamine and the delta opioid peptide receptor agonist SNC80 stimulated locomotor activity on the device. Amphetamine increased step velocity but not step length during its peak effect (40-70min after treatment), thus indicating detection of subtle amphetamine-induced effects. Animals showed a preference (74% of time spent) for the darkened half compared to the illuminated side. COMPARISON WITH EXISTING METHOD: Animals were videotaped within the chamber to compare quadrant crosses to detect motion on the device. The slope, duration and magnitude of quadrant crosses tightly correlated with overall locomotor activity as detected by MouseTrapp. CONCLUSIONS: We suggest that modern touch display devices such as MouseTrapp will be an important step toward automation of behavioral analyses for characterizing phenotypes and drug effects.
BACKGROUND: Monitoring mouse behavior is a critical step in the development of modern pharmacotherapies. NEW METHOD: Here we describe the application of a novel method that utilizes a touch display computer (tablet) and software to detect, record, and report fine motor behaviors. A consumer-grade tablet device is placed in the bottom of a specially made acrylic cage allowing the animal to walk on the device (MouseTrapp). We describe its application in open field (for general locomotor studies) which measures step lengths and velocity. The device can perform light-dark (anxiety) tests by illuminating half of the screen and keeping the other half darkened. A divider is built into the lid of the device allowing the animal free access to either side. RESULTS: Treating mice with amphetamine and the delta opioid peptide receptor agonist SNC80 stimulated locomotor activity on the device. Amphetamine increased step velocity but not step length during its peak effect (40-70min after treatment), thus indicating detection of subtle amphetamine-induced effects. Animals showed a preference (74% of time spent) for the darkened half compared to the illuminated side. COMPARISON WITH EXISTING METHOD: Animals were videotaped within the chamber to compare quadrant crosses to detect motion on the device. The slope, duration and magnitude of quadrant crosses tightly correlated with overall locomotor activity as detected by MouseTrapp. CONCLUSIONS: We suggest that modern touch display devices such as MouseTrapp will be an important step toward automation of behavioral analyses for characterizing phenotypes and drug effects.
Authors: Omar S Mabrouk; Daniel Z Semaan; Sarah Mikelman; Margaret E Gnegy; Robert T Kennedy Journal: J Neurochem Date: 2013-08-19 Impact factor: 5.372
Authors: Marcus A Westerman; Deirdre Cooper-Blacketer; Ami Mariash; Linda Kotilinek; Takeshi Kawarabayashi; Linda H Younkin; George A Carlson; Steven G Younkin; Karen H Ashe Journal: J Neurosci Date: 2002-03-01 Impact factor: 6.167
Authors: Emily M Jutkiewicz; Michelle G Baladi; John E Folk; Kenner C Rice; James H Woods Journal: J Pharmacol Exp Ther Date: 2007-11-06 Impact factor: 4.030
Authors: Jennifer A Beninson; Jennifer L Lofgren; Patrick A Lester; Madeline M Hileman; Daniel J Berkowitz; Daniel D Myers Journal: J Am Assoc Lab Anim Sci Date: 2018-05-01 Impact factor: 1.232
Authors: Alexander G Zestos; Colleen Carpenter; Youngsoo Kim; Malcolm J Low; Robert T Kennedy; Margaret E Gnegy Journal: ACS Chem Neurosci Date: 2018-11-08 Impact factor: 4.418